MedAdvisor – Rapid Growth of Patient Engagement Programs

12th December 2016 – ASX Announcement 

• Rapid growth of Patient Engagement Programs (PEPs), now with 18 medications part of educational programs, up from 8 medications 12 months ago
• PEPs reaching over 55,000 patients, delivering value to both manufacturers, pharmacies and patients
• MedAdvisor utilised by 9 of Australia’s largest pharmaceutical companies, including, Novartis, Bristol-Myers Squibb, GSK, AstraZeneca and now Pfizer
• PEPs continue to generate recurring revenue, with further growth anticipated as more manufacturers leverage the MedAdvisor platform across its growing patient base
• Healthnotes integration progressing well, with the merged team focused on creating a best in class technology offering

MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to provide an update on the rapid growth that its Patient Engagement Programs (PEPs) have achieved throughout 2016.

Consistent with MedAdvisor’s strategy to drive awareness and deliver value for pharmaceutical companies, the Company’s PEP offering is now being utilised by nine of Australia’s largest pharmaceutical companies including Novartis, Bristol-Myers Squibb, GSK, AstraZeneca, and now Pfizer (see announcement dated 8 November 2016). The significant uptake experienced among large pharmaceuticals companies evidences the huge benefits MedAdvisor delivers and demonstrates the global potential for the platform.

To view the full announcement, please click on the button below.